Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Revenue of Satsuma Pharmaceuticals, Inc. (STSA)
Revenue in 2022 (TTM): $
According to Satsuma Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Satsuma Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-58,313,000 | $-70,055,000 | $-69,163,000 |
| 2021 | $ | $ | $-50,616,000 | $-51,172,000 | $-51,264,000 |
| 2020 | $ | $ | $-47,213,000 | $-47,563,000 | $-47,674,000 |
| 2019 | $ | $ | $-27,693,000 | $-28,175,000 | $-28,515,000 |
| 2018 | $ | $ | $-7,199,000 | $-7,346,000 | $-7,346,000 |
| 2017 | $ | $ | $-5,147,000 | $-5,172,000 | $-5,172,000 |